- Популярные видео
- Авто
- Видео-блоги
- ДТП, аварии
- Для маленьких
- Еда, напитки
- Животные
- Закон и право
- Знаменитости
- Игры
- Искусство
- Комедии
- Красота, мода
- Кулинария, рецепты
- Люди
- Мото
- Музыка
- Мультфильмы
- Наука, технологии
- Новости
- Образование
- Политика
- Праздники
- Приколы
- Природа
- Происшествия
- Путешествия
- Развлечения
- Ржач
- Семья
- Сериалы
- Спорт
- Стиль жизни
- ТВ передачи
- Танцы
- Технологии
- Товары
- Ужасы
- Фильмы
- Шоу-бизнес
- Юмор
Innovision IPO Review (Good or Bad) GMP, Price, Financials, Apply or Avoid? #shorts
Innovision IPO Review (Good or Bad) GMP, Price, Financials, Apply or Avoid? #shorts
Innovision IPO 2026 is a ₹322.84 crore mainboard issue from a fast‑growing industrial/engineering player—but is it a good or bad IPO for listing gains and long‑term investors?
IPO details: total issue size ~₹322.84 crore (fresh issue ~₹255 crore + OFS ~₹68 crore); price band ₹521–₹548 per share; lot size 27 shares (minimum investment ~₹14,796 at upper band); IPO opens 10 March and closes 12 March; tentative listing on 17 March 2026 on NSE & BSE.
Business: Innovision is a high‑growth manufacturing/solutions company (industrial/engineering niche) with revenues scaling rapidly on the back of capacity expansion and a diversified B2B client base, but it also runs a relatively capital‑intensive, debt‑supported model.
Financials: total income has jumped from ~₹257.6 crore in FY23 to ~₹512.1 crore in FY24 and ~₹895.8 crore in FY25; PAT has similarly risen from ~₹8.2 crore to ~₹11.3 crore to ~₹30.7 crore, with improving EBITDA but still moderate margins and rising debt to fund growth.
Use of funds: fresh issue proceeds are primarily earmarked for capex/expansion, repayment/prepayment of borrowings and general corporate purposes, which should support growth while partly easing balance‑sheet pressure.
GMP today: Innovision IPO GMP is currently around ₹0 per share—flat to the upper band—indicating no clear listing gain signal yet and a wait‑and‑watch stance from the grey market.
One‑line view: strong top‑line growth with improving profits but rising leverage and zero GMP—makes Innovision a candidate mainly for investors who like growth + can digest balance‑sheet risk, while pure listing‑gain hunters and ultra‑conservative investors may prefer to skip or keep allocation small.
innovision ipo review, innovision ipo gmp today, innovision ipo good or bad, innovision ipo price band 521 548, innovision ipo dates 10 12 march 2026, innovision ipo apply or avoid, innovision ipo lot size 27 shares, innovision ipo details 2026, innovision financials fy25, high growth manufacturing ipo india, mainboard ipo 2026, listing gain ipo 2026, upcoming ipo 2026 india, growth plus debt ipo analysis, ipo for long term vs listing gains, indian ipo review 2026, stockbox ipo shorts
Видео Innovision IPO Review (Good or Bad) GMP, Price, Financials, Apply or Avoid? #shorts канала StockBox
Innovision IPO 2026 is a ₹322.84 crore mainboard issue from a fast‑growing industrial/engineering player—but is it a good or bad IPO for listing gains and long‑term investors?
IPO details: total issue size ~₹322.84 crore (fresh issue ~₹255 crore + OFS ~₹68 crore); price band ₹521–₹548 per share; lot size 27 shares (minimum investment ~₹14,796 at upper band); IPO opens 10 March and closes 12 March; tentative listing on 17 March 2026 on NSE & BSE.
Business: Innovision is a high‑growth manufacturing/solutions company (industrial/engineering niche) with revenues scaling rapidly on the back of capacity expansion and a diversified B2B client base, but it also runs a relatively capital‑intensive, debt‑supported model.
Financials: total income has jumped from ~₹257.6 crore in FY23 to ~₹512.1 crore in FY24 and ~₹895.8 crore in FY25; PAT has similarly risen from ~₹8.2 crore to ~₹11.3 crore to ~₹30.7 crore, with improving EBITDA but still moderate margins and rising debt to fund growth.
Use of funds: fresh issue proceeds are primarily earmarked for capex/expansion, repayment/prepayment of borrowings and general corporate purposes, which should support growth while partly easing balance‑sheet pressure.
GMP today: Innovision IPO GMP is currently around ₹0 per share—flat to the upper band—indicating no clear listing gain signal yet and a wait‑and‑watch stance from the grey market.
One‑line view: strong top‑line growth with improving profits but rising leverage and zero GMP—makes Innovision a candidate mainly for investors who like growth + can digest balance‑sheet risk, while pure listing‑gain hunters and ultra‑conservative investors may prefer to skip or keep allocation small.
innovision ipo review, innovision ipo gmp today, innovision ipo good or bad, innovision ipo price band 521 548, innovision ipo dates 10 12 march 2026, innovision ipo apply or avoid, innovision ipo lot size 27 shares, innovision ipo details 2026, innovision financials fy25, high growth manufacturing ipo india, mainboard ipo 2026, listing gain ipo 2026, upcoming ipo 2026 india, growth plus debt ipo analysis, ipo for long term vs listing gains, indian ipo review 2026, stockbox ipo shorts
Видео Innovision IPO Review (Good or Bad) GMP, Price, Financials, Apply or Avoid? #shorts канала StockBox
stock box STOCKBOX innovision ipo gmp today innovision ipo good or bad innovision ipo price band 521 548 innovision ipo dates 10 12 march 2026 innovision ipo apply or avoid innovision ipo lot size 27 shares innovision ipo details 2026 innovision financials fy25 high growth manufacturing ipo india mainboard ipo 2026 listing gain ipo 2026 upcoming ipo 2026 india growth plus debt ipo analysis indian ipo review 2026 stockbox ipo shorts Innovision IPO REVIEW
Комментарии отсутствуют
Информация о видео
9 марта 2026 г. 18:30:19
00:02:09
Другие видео канала





















